Samsung Biologics

207940.KO

664.47 USD

-2.24

-0.34%

Overview

Last close

664.47 usd

Market cap

47.29B usd

52 week high

754.39 usd

52 week low

499.98 usd

Target price

711.42 usd

Valuation

P/E

N/A

Forward P/E

53.1915

Price/Sales

15.7853

Price/Book Value

6.3033

Enterprise Value

47.18B usd

EV/Revenue

15.3227

EV/EBITDA

33.4827

Key financials

Revenue TTM

3.00B usd

Gross Profit TTM

1.04B usd

EBITDA TTM

1.35B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

16,342.85B usd

Net debt

N/A usd

About

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.